Comparing potential bispecific formats comprising of trastuzumab and a humanized OKT3

Bispecific antibodies are an increasingly important class of therapeutics, but their performance can vary widely depending on format and design. Learn how Absolute Antibody systematically compared 17 bispecific formats built from the same parental antibodies, and explore the findings of this comparison, including how Fc architecture, scFv placement, and interface stability affect expression and function. Plus, gain practical guidance on how to select and optimize bispecific designs, along with access to a reference panel that helps overcome common engineering challenges.